Childhood non-Hodgkin's lymphoma in Egypt: preliminary results of treatment with a new ifosfamide-containing regimen

Pediatric non-Hodgkin's lymphoma (NHL) constitutes 16% of pediatric malignancies reported to the National Cancer Institute (NCI) in Cairo. Since July 1985, we have treated 39 previously untreated pediatric NHL cases younger than 16 years of age (mean, 7.6 years) with a new protocol consisting o...

Full description

Saved in:
Bibliographic Details
Published in:Cancer chemotherapy and pharmacology 1989-07, Vol.24 Suppl 1 (S1), p.S20-S23
Main Authors: Gad-el-Mawla, N, Hussein, M H, Abdel-Hadi, S, el-Taneer, O, Adde, M, Magrath, I
Format: Article
Language:English
Subjects:
Adolescent
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Child
Child, Preschool
Combined Modality Therapy
Cytarabine - administration & dosage
Drug Evaluation
Egypt
Etoposide - administration & dosage
Female
Humans
Ifosfamide - administration & dosage
Infant
Lymphoma, Non-Hodgkin - drug therapy
Lymphoma, Non-Hodgkin - mortality
Lymphoma, Non-Hodgkin - surgery
Male
Methotrexate - administration & dosage
Remission Induction
Time Factors
Vincristine - administration & dosage
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pediatric non-Hodgkin's lymphoma (NHL) constitutes 16% of pediatric malignancies reported to the National Cancer Institute (NCI) in Cairo. Since July 1985, we have treated 39 previously untreated pediatric NHL cases younger than 16 years of age (mean, 7.6 years) with a new protocol consisting of alternating cycles: regimen A comprised cyclophosphamide, high-dose ara-C, Adriamycin and vincristine; regimen B consisted of ifosfamide, methotrexate and VP16, with intrathecal methotrexate. Diagnoses included 20 abdominal masses, 16 peripheral lymphadenopathies and 6 bony lesions. Histopathology according to the working formulation revealed 21 cases of small non-cleaved lymphoma, 6 lymphoblastic, 5 large-cell and 7 unclassified diffuse lymphomas. Responses were complete in 31 cases (82%) and partial in 4 cases (10%), and no response was obtained in 4 cases (8%). Overall survival was 82% in limited disease and 60% in extensive disease at 28+ months. This short-term ifosfamide-containing regimen proved its efficacy, with results matching those of other regimens used in the United States and Europe.
ISSN:0344-5704
1432-0843
DOI:10.1007/BF00253233